Neurofibromatosis type 1, including the highly aggressive malignant peripheral nerve sheath tumors (MPNSTs), is featured by the loss of functional neurofibromin 1 (NF1) protein resulting from genetic alterations. A major function of NF1 is suppressing Ras activities, which is conveyed by an intrinsic GTPase-activating protein-related domain (GRD). In this study, we explored the feasibility of restoring Ras GTPase via exogenous expression of various GRD constructs, via gene delivery using a panel of adeno-associated virus (AAV) vectors in MPNST and human Schwann cells (HSCs). We demonstrated that several AAV serotypes achieved favorable transduction efficacies in those cells and a membrane-targeting GRD fused with an H-Ras C-terminal motif (C10) dramatically inhibited the Ras pathway and MPNST cells in a NF1-specific manner. Our results opened up a venue of gene replacement therapy in NF1-related tumors.
Introduction
The RASopathy neurofibromatosis 1 is an autosomal dominant hereditary cancer syndrome that affects~1:3000 individuals [1, 2] . Neurofibromatosis 1 is caused by mutations of the neurofibromin 1 (NF1) tumor suppressor gene at 17q11.2, which encodes the GTPase-activating protein (GAP) NF1 that catalyzes the inactivation of Ras by accelerating GTP hydrolysis to GDP [3, 4] . In affected individuals, truncation or loss of NF1 results in constitutively activated Ras with subsequent activation of the RAF-MEK-ERK cascade. This Ras hyperactivation supports the frequent development of multiple benign tumors, as in plexiform and cutaneous neurofibromas, and less frequently malignancies.
A hallmark of neurofibromatosis 1 is the presence of benign plexiform neurofibromas (pNFs) in which biallelicinactivating mutations in the NF1 gene in Schwann cells occur, thus providing a selective growth advantage to a normal Schwann cell [2, 5] . About 8-13% of pNFs undergo cancerous transformation into a malignant peripheral nerve sheath tumor (MPNST) through a course of molecular evolution during which accumulated genetic mutations in CDKN2A/B, TP53, and other genes, as well as epigenetic alternations affect the regulation of multiple cellular processes [2, 6] . This transformation evolves over many years and typically affects young adults with neurofibromatosis 1 in their 20s-30s, with MPNSTs representing the leading cause of mortality in this patient population [7, 8] .
The treatment of MPNSTs has unfortunately been extremely challenging. To date, surgery is the only treatment modality proven to have survival benefit for MPNSTs. However, even when maximal surgery with wide surgical margins is feasible, these tumors are almost never curable [8, 9] and about 50% of patients will succumb to this condition within 5 years after initial diagnosis, reflecting the urgent need for new and more effective therapeutics for this cancer.
One very promising but largely unexplored concept in the treatment of NF1-related MPNSTs is gene therapy. Over the past years, delivery vectors based on recombinant adenoassociated virus (AAVs) have shown great promise and achieved clinically meaningful long-term gene expression leading to regulatory approval for some conditions such as hemophilia, biallelic RPE65 mutation-mediated inherited retinal dystrophy, and spinal muscular atrophy type I [10] [11] [12] .
The recombinant AAV is a non-pathogenic, nonreplicating parvovirus, because rep and cap genes are cloned in a trans-plasmid without inverted terminal repeats. To date, more than 100 natural occurring human and nonhuman primate AAV serotypes have been identified [13] . Unlike lentivirus (LV), it does not cause any human disease and has a reduced carcinogenicity, because it only rarely integrates into the genome of the host cell. It is capable of infecting both dividing and quiescent cells with a low host immune recognition. Notably, advancements in our understanding of AAV capsid structure have facilitated the rational design of AAV capsids to restrict or redirect viral tropism and transduction, and considerable progress in both AAV capsid library development and screening methodology has enabled directed evolution of AAV capsids, which will ultimately ensure that transgene expression is reproducible, robust, and occurs over an extended period [13] [14] [15] .
Gene delivery vectors based on AAVs have a packaging capacity of up to~4.7 kb at near wild-type (WT) titers and infectivity; beyond this size, packaging efficiency markedly decreases and genomes with 5′-truncations become encapsidated [14] . Although NF1' cDNA of 8.5 kb is too large for AAV vectors, the NF1-GAP-related domain (NF1-GRD), ã 1 kB small subunit of the gene, is presumably solely responsible for deactivating Ras activity [16, 17] , thus making neurofibromatosis 1 uniquely suitable for AAVbased gene delivery.
In this study, we have screened a panel of available AAV vectors in MPNST and primary Schwann cells to profile transduction efficacies of different serotypes, in order to reveal potential templates for future engineering of the AAV capsid. We also tested the inhibition of the Ras pathway in NF1-related MPNST cells using GRD optimized for membrane targeting.
Materials and methods

Tissue culture and cell lines
Human NF1-associated MPNST cell lines NF90.8 and ST88-14 were provided by Dr Michael Tainsky (Wayne University, Detroit, MI) and sNF96.2 was purchased from ATCC (Manassas, VA). NF90-8, ST88-14, sNF96.2, and STS26T MPNST cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) (ATCC) supplemented with 10% fetal bovine serum (FBS) (Sigma) and penicillin/ streptomycin (Gibco). These cell lines were not authenticated. Human Schwann cells (HSCs) isolated from spinal nerve were purchased from ScienCell Research Laboratories and maintained in DMEM media supplemented with 3% FBS, penicillin/streptomycin, and heregulin-1 (PeproTech) 20 ng/ml and 2 μM forskolin (Sigma). All cells were tested and found free of mycoplasma contamination.
Reagents and antibodies
The rabbit anti-phospho-Erk1/2 (p44/42 MAPK) (Thr202/ Tyr204) antibody (#9101, Lot 23) and anti-Erk1/2 (p44/42 MAPK) antibody (#9102, Lot 27) were purchased from Cell Signaling Technologies. Rabbit anti-NF1 antibody (A300-140A, Lot 3) was purchased from Bethyl Laboratories, mouse anti-hemagglutinin (HA) antibody (26183, Lot RJ241582) was purchased from Invitrogen, and anti-β-Actin (C-11, SC-1615HRP, Lot G3015) horseradish peroxidase antibody was purchased from Santa Cruz Biotech. Active Ras Detection Kit (#8821, antibody Lot 7) was purchased from Cell Signaling Technology. NucBlue Live Ready Probes was purchased from Invitrogen.
NF1-GRD constructs
Human NF1 transcript variant 2 (NM_000267.3) of 2818 amino acids (AAs) was used as the template sequence. The GRD sequence of NF1 (AA 1172-1538), as described before [18] , was cloned with a C-terminal 2xHA tag into the LV pFUGW and pscAAV-MCS (Cell Biolabs, VPK-430) vectors. To create a membrane-targeting GRD construct (GRD-C10), a 2xHA sequence was fused to the N terminus of GRD and a sequence encoding the H-Ras C-terminal 10 AA (GCMSCKCVLS) containing the CAAX motif was attached in frame to the GRD C terminus.
Lentiviral production and transduction
Enhanced green fluorescent protein (EGFP) or GRD-2HA was cloned in pFUGW vector and the plasmid was transfected along with CMVΔR8.91 and pMD.G in 293T cells by Lipofectamine 2000 (Invitrogen). Virus was collected after 48 h and infected MPNST cells by incubating with 8 μg/ml polybrene (Sigma).
AAV plasmids
pscAAV was purchased from Cell Biolabs, Inc. We obtained 13 hybrid pAAV-Rep-Cap (pAAV-RC) vectors, which encode the rep of AAV2 and variable cap genes of different serotypes. Among them, pAAV2-RC was purchased from Stratagene, pAAV-RC3B, pAAV-RC4, pAAV-RC6, and pAAV-DJ were purchased from Cell Biolabs, and pAAV2/1, pAAV2/5 JC, pAAV2/7, pAAV2/ 8, pAAV9n, pAAV2/rh10, pAAV2/hu11, and pAAV2/ rh32.33 were obtained from Penn Vector Core of the University of Pennsylvania. For AAV packaging, the pHelper plasmid (Stratagene) and AAVpro-293T cells (Clontech) were used.
AAV production and purification pAAV-Rep-Cap, pscAAV, and pHelper plasmids in equal amount were transfected in AAVpro-293T cells by Lipofectamine 2000 in DMEM media supplemented with 10% FBS. After 3 days, cells were collected and AAVs were purified by AAVpro Purification Kit of Clontech following the manufacturer's instruction. Viral titers were determined by AAVpro Titration Kit from Clontech using realtime PCR. 
AAV transduction and fluorescence microscopy
Immunofluorescence staining
The staining followed the procedure described before [19] . Cells were grown in medium on chamber slides (Nunc) and treated as indicated. Cells were washed with phosphatebuffered saline (PBS) and fixed for 10 min with 4% paraformaldehyde solution, and permeated with methanol for 2 min with three washes in PBS in between and after. The slides were first blocked by 10% goat serum in PBS for 1 h at room temperature (RT) and incubated with the first antibody, and subsequently with AlexaFluor 488 (Green) secondary antibody (Invitrogen) in 10% goat serum in PBS at RT. They were then washed three times in PBS in between and after. After staining, the slides were covered with mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories) and examined on a fluorescence microscope.
Western blottings
Cells were lysed in buffer as described previously [19, 20] . Briefly, cells were suspended in lysis buffer (10 mM TrisHCl pH 7.5, 130 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 20 mM sodium phosphate pH 7.5, 10 mM sodium pyrophosphate pH 7.0, 50 mM NaF, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail [Roche]) and kept on ice for 10 min before being centrifuged. Cell lysates were heated for 5 min with LDS Sample Buffer (Invitrogen) supplemented with 100 mM dithiothreitol (DTT) before loading onto a 4-12% NuPAGE Bis-Tris Gel (Invitrogen). After transfer to a polyvinylidene difluoride membrane (Bio-Rad), immunostaining was performed according to standard procedure. Signals were visualized by the Super Signal chemiluminescent system (Pierce, Rockford, IL). Experiments were repeated twice.
Assay of active Ras
Ras activities in MPNST cells were examined by the Active Ras Detection Kit (#8821, Cell Signaling Technology) following the manufacturer's instuction. Briefly, the cell lysates were incubated with GST-Raf1-RBD and glutathione resin. After wash and centrifugation, the bound fractions of Ras were dissociated and denatured in SDS sample buffer with DTT and examined by anti-Ras western blotting. Pre-incubating the lysates with 0.1 mM GTPγS or 1 mM GDP before binding with GST-Raf1-RBD created positive or negative control, respectively. Experiments were repeated twice.
Cell growth assay
The viable cells were measured with Cell Counting Kit-8 (Dojindo Laboratories, Japan) containing WST-8 tetrazolium salt at 450 nm on a PerkinElmer VICTOR3 plate reader. Three biological samples were measured in each experiment.
Flow cytometry
Analysis of EGFP-positive cells. NF90-8 cells in six-well plates were incubated with AAV-DJ-EGFP at MOI 1000 or 5000 for 36 h. Cells were collected by trypsinization, counterstained by incubating with 28 mM DAPI for 5 min in the flow buffer (PBS with 4% FBS and 1 mM EDTA), washed, and analyzed by a BD FACSAria Fusion at the FITC channel. Control was untransfected cells. Three independent samples were measured and data were analyzed by two-tailed t-test.
Staining of GRD-2HA and GRD-C10-2HA transfected by AAV-DJ. NF90-8 cells in six-well plates were incubated with AAV-DJ control, AAV-DJ-GRD-2HA, or AAV-DJ-GRD-C10-2HA at MOI 5000 for 36 h. Cells were trypsinized, fixated by the IC fixation buffer (Invitrogen, #00-8222), permeabilized by the permeabilization buffer (Invitrogen, #00-8333), and incubated with anti-HA antibody conjugated with AlexaFluor 647 (R&D Systems, #IC6875R) at 5 µl/10 6 cells in 100 µl permeabilization buffer for 45 min at RT. Cells were then washed twice in 2 ml permeabilization buffer, resuspended in 0.5 ml flow buffer, and analyzed by a BD FACSAria Fusion. Data were obtained from three independent samples and analyzed by two-tailed t-test.
Propidium iodide (PI) staining. Cells were plated in sixwell plates and transduced with indicated AAVs. After 2 days, cells were trypsinized, washed, pelleted, and fixated with 70% ethanol at the final concentration on ice for 15 min. Cells were then centrifuged and incubated with 500 µl PI solution in PBS (50 µg/ml PI, 0.1 mg/ml RNase A, 0.05% Tritin X-100) at 37°C for 40 min. Subsequently, cells were washed and resuspended in PBS, and analyzed with a BD FACSymphony A3 flow cytometer using the PE-Gr-A channel. Results were analyzed with FlowJo version 10.
Statistical analysis
The results are presented as a mean value ± SD. Data were analyzed by GraphPad Prism 5.0. The p-values were determined by a Mantel-Cox test. A p-value < 0.05 was accepted as statistically significant. Sample sizes were chosen to achieve statistical significance.
Results
NF1-GRD suppressed the RAS activity and the growth of MPNST cells
Expressing the GRD domain of NF1 could restore normal growth in NF1−/− hematopoietic cells, fibroblasts, and neural stem cells [16, 17] . Likewise, the effects of the GRD have also been demonstrated in MPNST cells [21, 22] .
In this study, we first subcloned the GRD domain of human NF1 into the pFUGW LV vector with a C-terminal double HA tag (2HA) for sensitive in vitro and in vivo detection. Human MPNST cells NF90.8, sNF96.2, and ST88-14 were derived from patients with neurofibromatosis 1 and lacked the WT NF1 gene, whereas both STS26T cells derived from a sporadic MPNST and primary HSCs isolated from spinal nerve expressed functional NF1 [23] . Figure 1a confirmed the expression status of NF1 protein in these cells. As shown in Fig. 1b , the GRD-2HA construct was able to significantly reduce the aberrant Ras activity in ST88-14 and NF90.8 cells in the GST-Raf1-RBD pulldown assay, suggesting that the GAP domain of NF1 compliments the inability of these cells to inactivate RAS. The replacement of the NF1-GRD via lentiviral transduction significantly suppressed the growth of NF90.8, sNF96.2, and ST88-14 cells, compared with the EGFP construct as control (Fig. 1c) .
Next, we compared the transduction efficacy of a panel of commercially available AAV vectors in MPNST and primary HSCs by expressing EGFP and quantifying the green fluorescent signals. We used 13 hybrid pAAV-RepCap (pAAV-RC) vectors, which encode the rep of AAV2 and variable cap genes of different serotypes, including AAV1 (pAAV2/1), AAV2 (pAAV2-RC), AAV3B (pAAV-RC3B), AAV4 (pAAV-RC4), AAV5 (pAAV2/5 JC), AAV6 (pAAV-RC6), AAV7 (pAAV2/7), AAV8 (pAAV2/ 8), AAV9 (pAAV9n), AAV10 (pAAV2/rh10), AAV11 (pAAV2/hu11), and AAV32/33 (pAAV2/rh32.33), as well as the synthetic AAV-DJ (pAAV-DJ) [24] [25] [26] [27] [28] , along with the pHelper and self-complimentary pscAAV (pscAAV-MCS) expression vector to enhance the transduction [29] . The pscAAV vector uses the cytomegalovirus promoter to express the transgene. After production, purification and quantification of AAVs, 5000 ST88-14, NF90-8, or sNF96.2 cells were plated in 96-well plates and incubated with indicated AAVs at MOI 1000 or 5000. Cells were allowed to grow 5 days to reach complete confluence as examined optically by microscope. Green fluorescent signals in each well were quantified by a plate reader, which reflected the expression levels of EGFP in the transduced cells. At an MOI of 5000, AAV2, 3B, and DJ demonstrated superior transduction of EGFP in ST88-14 cells, whereas in NF90-8 cells, AAV1, 2, 3B, 6, and DJ showed significant transduction in contrast to other AAVs (Fig. 2a, c) . Cells incubated at MOI of 1000 followed a similar trend. The results were consistent with the observation of the fluorescence microscopy, where all the cells were photographed and either selectively shown in Fig. 2b, d or not shown. In sNF96.2 cells, AAV1, 2, 3B, and DJ again stood out both at MOI 5000 and 1000 (Fig. 3a, b) . Using flow cytometry, we measured in average 98.7% and 99.1% NF90-8 cells were positive of EGFP at MOI 1000 and 5000 of AAV-DJ-EGFP, respectively, with higher expression levels observed at MOI 5000 ( Supplementary Fig. 1 ). It has been established that NF1-related MPNSTs originate from NF1-haploid Schwann cells [2, 30] . Restoring NF1 function in those NF1-haploid Schwann cells via gene replacement therapy could thus also benefit patients before the malignant transformation occurs and possibly prevent this often fatal complication. To test this, we transduced primary HSCs that are positive of S-100 staining ( Fig. 3c ) with 13 AAV vectors encoding EGFP and found AAV 1, 2, 6, and DJ delivered EGFP most efficaciously (Fig. 3d, e) .
Next, we tested GRD constructs with AAV-DJ, one of the consistently efficacious AAV vectors among MPNST and HSCs. As R as proteins are attached to the cellular membrane through prenylation and palmitoylation of cysteine residues including a CAAX motif located in the Cterminal hypervariable region (HVR) that confers targeting to the plasma membrane [31] [32] [33] , we created a GRD construct fused with the 10 AAs of H-Ras C terminus (C10) containing the palmitoylation sites and CAAX motif, with a double HA tag at the N terminus (called 'GRD-C10'). When transduced by AAV-DJ in NF90-8 cells, GRD-C10 drastically outperformed GRD in suppressing the phosphorylation of Erk1/2 (pErk1/2) in that no pErk1/2 signal was detected with GRD-C10 compared to a reduced, but still detectable, pErk1/2 signal with GRD, despite a relatively low GRD-C10 expression level in those cells (Fig. 4a) . Using intracellular anti-HA staining and flow cytometry, we found that on average 13.2% and 9.8% of NF90-8 cells were stained positive 36 h after transfected by AAV-DJ-GRD and AAV-DJ-GRD-C10 at MOI 5000, respectively ( Supplementary Fig. 2) . Immunofluorescence staining of HA demonstrated the membrane-targeting of GRD-C10 α-S100 (Fig. 4b) . GRD-C10 markedly outperformed GRD in suppressing the growth of ST88-14, NF90-8, and sNF96.2 cells (Fig. 4c-e) . Cell cycle analysis of NF90-8 and ST88-14 cells indicated significantly less cells in G2/M phase and more cells in Sub-G0 48 h after transduction with AAV-DJ-GRD-C10 compared to those with control AAV-DJ (Fig. 4f, g, Supplementary Fig. 3 ). In contrast, despite being transducible with AAV-DJ (Fig. 5a, b) , STS26C cells, a spontaneous MPNST cell line with intact NF1 (Fig. 1a) , were not affected by GRD and GRD-C10 (Fig. 5c) . Similarly, HSCs was not suppressed by GRD at all and also not by GRD-C10 at a significant level (Fig. 5d) .
Discussion
The major challenge facing therapies using AAVs is the poor efficacy in delivery, to which many efforts have been directed in modifying and optimizing the AAV cap gene [34] . For example, aiming to improve targeting and reduce anti-AAV immunity, recombinant AAV-DJ was created via DNA shuffling and immunoselection from cap genes of eight natural serotypes and markedly outperformed all the parental AAV vectors in vitro [28] . Further engineering of AAV-DJ resulted in drastically improved delivery in various mice tissues [28, 35] . In this study, we analyzed the transduction efficacies of recombinant vectors distinct from each other only on capsids of 12 natural serotypes of human and monkey origins, and the synthetic AAV-DJ in various MPNST cells and HSCs. The consensual AAV1, 2, 3B, and DJ, as well as AAV6, which transduced HSCs and MPNST cell line NF90-8 particularly efficiently, can be used for further in vivo testing and should be included as templates in future engineering efforts to improve targeting of MPNSTs and HSCs.
Although AAV has not been tested with MPNST cells in prior publications, Hoyng et al. [36] reported the transduction of primary HSCs and rat Schwann cells with AAV serotypes 1-9 carrying GFP in culture and in nerve segments. In that study, AAV2 and AAV6 outperformed other vectors in cultured HSC, which is largely consistent with our finding in Fig. 3d . Nuclei were stained by DAPI in blue. c-e Inhibition of MPNST cells by GRD and GRD-C10 transduced by AAV-DJ. NF90-8, ST88-14, and sNF96.2 cells were plated in 96-well plates and incubated with AAV-DJ carrying EGFP, GRD-2HA, or 2HA-GRD-C10 constructs at MOI 5000. After 4 days, viable cells were measured. Three biological samples were measured in each data point and P-values were evaluated by two-tailed t-test. f, g NF90-8 and ST88-14 cells were transduced by control AAV-DJ or AAV-DJ-2HA-GRD-C10 at MOI 5000. After 2 days, cells were collected, stained by propidium iodide, and analyzed by flow cytometry (n = 3). Fractions were calculated and P-values were evaluated by two-tailed t-test NF1 is a large protein with various domains of complex functionalities, including cysteine serine-rich domain, tubulin-binding domain, GRD, Sec14, PH-like domain, and FAK-binding region [37] . A GRD version of 333 AAs (NF1-333, AA 1198-1530) has been extensively investigated, which revealed a central minimal GAP domain of 230 AA (AA 1248-1477) and flanking extra regions that also appeared to mediate important GAP-related functions and interactions [37] [38] [39] . In physiological conditions, NF1 protein is recruited to the plasma membrane by interacting with Spred1, which has been mapped between Spred1 EVH1 domain and GRD's N-(AA 1202-1217) and Cterminal (AA 1511-1530) extra regions [40] [41] [42] . In this study, we used a slightly larger GRD sequence (AA 1172-1538) in our construct with a double HA tag [18] . This construct presented a diffused subcellular distribution in MPNST cells upon viral transduction. The C-terminal HVRs of Ras proteins with the CAAX motif contain cysteine residues subject to prenylation and palmitoylation and confer the targeting to the plasma membrane. For example, the C-terminal 11 AA, 10 AA, and 20 AA of respective N-Ras, H-Ras, and K-Ras4B have been shown to re-target an exogenously expressed protein to the plasma membrane [31, 33] . In order to improve the targeting on membrane-associated Ras proteins, GRD was fused with an H-Ras C10 sequence containing cysteine 181 and 184, as well as the CAAX motif. This GRD-C10 construct drastically enhanced GRD's potency in suppressing pErk1/2 and the growth of NF1-related MPNST cells with remarkable specificity while NF1-unrelated MPNST cells and HSC remained unaffected. Thus, given its potency and specificity, GRD-C10 would be therapeutically well suited as a treatment agent in patients with NF1-related MPNSTs and also as a tumor preventative in NF1-haploid individuals in whom tumors have not developed yet. In such a therapy, a noticeable efficacy would entail almost all of the MPNST cells or the majority of the NF1-haploid Schwann cells to receive the GRD-C10 transgene, since the nontransduced populations exhibit a clear growth advantage. With the current available tools for in vivo gene delivery, this would be only feasible with a drastically improved AAV vector for MPNST or Schwann cells, which could be achieved through protein engineering of the AAV capsids. We further reason that a gene replacement therapy may have an especially good chance of success as a preventative measure before the malignant transformation to MPNST occurs by repeatedly targeting NF1-haploid Schwann cells that grow less aggressively than MPNST cells. Alternatively, approaches to upregulate the expression of NF1 on the intact allele in NF1-haploid cells can also be considered,
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A. e.g., via techniques with specific recognition such as CRISPR-dCas9-VPR, where the nuclease-null Cas9 is fused with a tripartite activator, VP64-p65-Rta (VPR) [43] . However, although the latter approach could produce more copies of the full-length NF1, it will also face acute limitations in the cloning capacity and transduction efficiency of AAV vectors.
